A traditional treatment for heart failure appears to be equally protective in preventing death or hospitalization among African-American patients, as compared to white patients, according to a study at Henry Ford Hospital in Detroit. Angiotensin converting enzyme inhibitors (ACE) and angiotensin receptor blockers (ARB) are standard heart failure treatments…
Read rest of story »
In Standard Heart Failure Treatment, Study Finds No Difference In Results By Race
May 12th, 2012News From The Journal Of Clinical Investigation: May 8, 2012
May 9th, 2012VASCULAR BIOLOGY Genetic variation contributes to high blood pressure High blood pressure, or hypertension, is a pervasive problem that increases risk for a number of diseases including stroke, heart attack, peripheral arterial disease and chronic kidney disease. Many molecular pathways contribute to the development of hypertension, including nitric oxide signaling…
Read rest of story »
Managing Hypertension – Using Single Tablet Regimens
May 5th, 2012The Journal of Medical Economics reveals that hypertensive patients who are treated with a single tablet regimen (STR) as part of their therapy had a considerable reduction in serious cardiovascular events at a neutral cost as compared with individual component therapies…
Read rest of story »
Teens With Abnormal Levels Of Uric Acid At Increased Risk For Hypertension
May 4th, 2012Teens with high levels of uric acid appear to be at increased risk for high blood pressure, according to results of research from scientists at Johns Hopkins Children’s Center…
Read rest of story »
Triple Combination Therapy Proves Effective For Treating Hypertension
May 4th, 2012Results from two studies were presented at the 22nd European Society of Hypertension (ESH) in London highlighting the benefits of triple combination therapy for individuals suffering from hypertension. The results add to clinical understanding of olmesartan(O)/amlodipine(A)/hydrochlorothiazide(H) (O/A/H) triple combination therapy (Sevikar HCT®)…
Read rest of story »
Pulmonary Arterial Hypertension – Phase III SERAPHIN Outcome Study Meets Primary Endpoint
May 2nd, 2012The initial analysis of Actelion’s macitentan, a novel dual endothelin receptor antagonist that resulted from a tailored drug discovery process, has met its primary endpoint in a pivotal, long term, event-driven SERAPHIN Phase III trial…
Read rest of story »
PTSD Symptoms May Be Relieved By Some Blood Pressure Drugs
May 2nd, 2012Traumatized people who take a class of common blood pressure medications tend to have less severe post-traumatic stress symptoms, researchers have found. The finding suggests that ACE (angiotensin converting enzyme) inhibitors or ARBs (angiotensin receptor blockers) could be valuable tools for treating or preventing post-traumatic stress disorder…
Read rest of story »
News From The Journal Of Clinical Investigation: April 30, 2012
May 2nd, 2012METABOLISM: Driving the preference for fatty foods The World Health Organization recognizes obesity as global pandemic that threatens the health of millions of people. A number of factors contribute to the development of obesity, including complex changes in cellular pathways…
Read rest of story »
Obesity In Pregnancy, Fetal Growth And Stillbirth
May 2nd, 2012Obesity during pregnancy puts women at higher risk of a multitude of challenges. But, according to a new study presented at the American Institute of Ultrasound in Medicine annual convention, fetal growth restriction, or the poor growth of a baby while in the mother’s womb, is not one of them…
Read rest of story »
Finding In Arginine Paradox Study Translates Into Treatment For Teen
May 1st, 2012In the spring of 2010, Baylor College of Medicine’s Dr. Brendan Lee received a desperate email from the mother of one of his patients. The teen – who had been Lee’s patient for most of his life – was in hypertensive crisis and none of the usual treatments could bring his blood pressure down to normal…
Read rest of story »
